RT Journal Article
SR Electronic
T1 Activity of LaSOM 65, a Monastrol-derived Compound, Against Glioblastoma Multiforme Cell Lines
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4463
OP 4468
VO 33
IS 10
A1 CRISTIANE SANTOS STUEPP
A1 FABRÍCIO FIGUEIRÓ
A1 FRANCIANE BRACKMANN MENDES
A1 ELIZANDRA BRAGANHOL
A1 ANDRESSA BERNARDI
A1 RUDIMAR LUIZ FROZZA
A1 CHRISTIANNE GAZZANA SALBEGO
A1 RÔMULO FARIA SANTOS CANTO
A1 DENNIS RUSSOWSKY
A1 VERA LUCIA EIFLER-LIMA
A1 ANA MARIA OLIVEIRA BATTASTINI
YR 2013
UL http://ar.iiarjournals.org/content/33/10/4463.abstract
AB Background/Aim: Despite recent progress in glioblastoma treatment, prognosis is still poor. Monastrol is a kinesin spindle protein (KSP) inhibitor and anticancer effects for this molecule have been reported. Here we describe the effect of LaSOM 65, a monastrol derivated compound, against glioma cell lines. Materials and Methods: Cell counting, viability assay, lactate dehydrogenase (LDH) activity, cell-cycle analysis, immunofluorescence and organotypic hippocampal slice cultures were performed. Results: LaSOM 65 reduced cell number and cell viability of gliomas cells, but did not cause arrest in the cell cycle at the G2/M phase. Measurement of LDH activity showed that LaSOM 65 induces necrosis after 48 h of treatment. Conclusion: LaSOM 65 appears to a be promising new molecule to treat glioblastoma since it promotes a decrease of cell growth and cell viability of glioma cells in vitro and does not induces the neurotoxic characteristics of the anti-mitotic drugs currently used.